Traditional antiphospholipid antibody detection exhibits significant limitations in the precise diagnosis and treatment of obstetric antiphospholipid syndrome (OAPS). This article systematically reviews the research progress of novel biomarkers in the field of OAPS, explores their clinical application prospects, and primarily summarizes the potential value of integrating the aforementioned indicators into a composite risk assessment model to better guide early risk stratification and individualized targeted treatment for high-risk pregnant women. It provides theoretical references for advancing OAPS towards precise management.
